{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:12:35Z","timestamp":1762542755762},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ijrobp.2017.09.048","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T13:19:15Z","timestamp":1507727955000},"page":"498-506","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Reduced Mortality Risk in the Recent Era in Early-Stage Hodgkin Lymphoma Patients Treated With Radiation Therapy With or Without Chemotherapy"],"prefix":"10.1016","volume":"100","author":[{"given":"Chirayu G.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Michaelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Silver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen J.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.09.048_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/bjc.2012.228","article-title":"Long-term survival after treatment for Hodgkin's disease (1973-2002): Improved survival with successive 10-year cohorts","volume":"107","author":"Bessell","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/bjh.13903","article-title":"Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: Report of the Childhood\/Adolescent\/Young Adult Cancer Survivors Research Program and the BC Cancer Agency Centre for lymphoid cancer","volume":"172","author":"Bhuller","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib4","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib5","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib6","doi-asserted-by":"crossref","first-page":"djv018","DOI":"10.1093\/jnci\/djv018","article-title":"Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood","volume":"107","author":"Matasar","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib7","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-Year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib9","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/oxfordjournals.aje.a116664","article-title":"Utility of the National Death Index for ascertainment of mortality among Cancer Prevention Study II Participants","volume":"137","author":"Calle","year":"1993","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib11","series-title":"Modeling Survival Data in Medical Research","author":"Collett","year":"2003"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib12","first-page":"135","article-title":"The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease","volume":"124","author":"Evens","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib13","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib14","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjh.12878","article-title":"Guidelines for the first line management of classical Hodgkin lymphoma","volume":"166","author":"Follows","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib16","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ijrobp.2014.06.069","article-title":"A decade of comparative dose planning studies for early-stage Hodgkin lymphoma: What can we learn?","volume":"90","author":"Maraldo","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib19","first-page":"1182","article-title":"Combined-modality therapy for early-stage Hodgkin lymphoma: Maintaining high cure rates while minimizing risks","volume":"26","author":"Kelsey","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib20","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s00520-015-2666-0","article-title":"Symptom burden and integrative medicine in cancer survivorship","volume":"23","author":"Cutshall","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/annonc\/mds243","article-title":"Influence of new late effects on quality of life over time in Hodgkin lymphoma survivors: A longitudinal survey study","volume":"24","author":"Khimani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib22","unstructured":"Life Tables for the United States Social Security: Table\u00a03\u2014Historical and assumed ultimate average annual percentage reductions in central death rates by sex, age group and cause of death. Available at: https:\/\/www.ssa.gov\/OACT\/NOTES\/as120\/LifeTables_Tbl_3.html. Accessed March 31, 2017."},{"key":"10.1016\/j.ijrobp.2017.09.048_bib23","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: Updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib24","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdr551","article-title":"Lung malignancies after Hodgkin lymphoma: Disease characteristics, detection method and clinical outcome","volume":"23","author":"Schoenfeld","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib25","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1002\/cncr.26257","article-title":"Survival after second primary lung cancer: A population-based study of 187 Hodgkin lymphoma patients","volume":"117","author":"Milano","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2014.06.013","article-title":"Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: A cost-effectiveness analysis","volume":"90","author":"Wattson","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib28","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib30","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2012.46.5732","article-title":"Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma","volume":"31","author":"Ng","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib31","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijrobp.2009.11.013","article-title":"Radiation for Hodgkin's lymphoma in young female patients: A new technique to avoid the breasts and decrease the dose to the heart","volume":"79","author":"Dabaja","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib34","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib35","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin's lymphoma: An analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib36","doi-asserted-by":"crossref","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib38","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2012.45.2714","article-title":"Temporal trends in mortality from diseases of the circulatory system after treatment for Hodgkin lymphoma: A population-based cohort study in Sweden (1973 to 2006)","volume":"31","author":"Eloranta","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib39","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ijrobp.2011.09.020","article-title":"Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma","volume":"83","author":"Maraldo","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.2014.58.7543","article-title":"Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: Analysis of the National Cancer Data Base","volume":"33","author":"Olszewski","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.09.048_bib41","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2015.06.039","article-title":"Early-stage classic Hodgkin lymphoma: The utilization of radiation therapy and its impact on overall survival","volume":"93","author":"Parikh","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617339548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617339548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T21:02:26Z","timestamp":1573506146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617339548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0360301617339548"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.09.048","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced Mortality Risk in the Recent Era in Early-Stage Hodgkin Lymphoma Patients Treated With Radiation Therapy With or Without Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.09.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}